BioSpace News Archive

Applied UV, Inc. announced that in addition to its exclusive Joint Distribution and Licensing Agreement with Akida Holdings LLC that was announced in a press release on September 8, 2020, it has signed a non-binding letter of intent to explore the possibility of acquiring certain key assets of Akida, including Akida’s rights to the manufacture and sale of the Airocide™ System of patented...

Eargo Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 19, 2020.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced financial results for the three-months ended September 30, 2020.

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel 2020 Virtual Healthcare Conference November 16, 2020 9:20 a.m. EDT Jefferies Virtual London Healthcare Conference November

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA ® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...

EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced financial results for the quarter ended September 30, 2020 and provided an update on recent corporate and operational activities.

Conformis, Inc. announced that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.

Product revenue for the first nine months of 2020 increased 29 % year-over-year to $ 30.8 million R olling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter of 2021 and be completed by the end of the second quarter of 2021

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “We are excited to have US WorldMeds in full control of our SYMJEPI product now that the transition from Sandoz has been completed. We expect to see the full impact of this transition going

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced it has appointed Kimberly Banks MacKay to serve as Senior Vice President General Counsel and Corporate Secretary, effective December 8, 2020.